SARS-CoV-2 Pseudovirus, D614G variant

Comprehensive Neutralization Assay Solutions for Advancing COVID-19 Research

Get your pseudovirus

D614G Pseudovirus Advantages

We produce a pseudovirus pseudotyped with the Spike Glycoprotein of SARS-CoV-2 virus D614G variant, also known as Wuhan-Hu-1 variant (GenBank: MN908947). These pseudoviruses carry a modified genome that expresses a luciferase or a GFP reporter gene.

Up to 1,000 reactions per mL (96-well plate)

Get a signal-to-background ratio of ≥10³ with 1 µL per well

Infectious titer of at least 10⁵ RLU/µL

The transduction efficiency is evaluated using HEK293 ACE2⁺ cells.

Lot to lot functionally validated

Infectivity and neutralization are evaluated for each batch

Lead Time: 2 - 3 week

We provide you with freshly produced pseudoviruses

QC report Order Now

Features

Enable specific detection

Expression of Spike glycoprotein as the sole surface antigen

Enhanced safety

Our pseudoviruses use a 3rd-generation lentivirus core and must be handled in BSL-2 conditions

Characterization of thermal stability

Stable at least 6 month at -80 °C

Support high-throughput screening

QR report Order Now

Applications

Pseudoviruses provide a safe and versatile platform for SARS-CoV-2 virus research and the development of therapeutic countermeasures. SARS-CoV-2 pseudoviruses have several important applications in research and development, including:

Vaccine Development

They are used to test the efficacy of new vaccines by evaluating their ability to induce neutralizing immune responses without the need for live pathogenic viruses.

Neutralizing Monoclonal Antibody Screening

Pseudoviruses enable rapid and safe screening of monoclonal antibodies targeting specific strains of the SARS-CoV-2 virus.

Antiviral Resistance Studies

They help study viral mutations and evaluate how these mutations affect sensitivity to antiviral treatments.

Fundamental Research on Viral Entry

Pseudoviruses are used to understand the mechanisms of viral entry into host cells, which is crucial for developing new therapies targeting these processes.

Treatment Efficacy Testing

They allow for the quick assessment of new antiviral agents’ effectiveness in controlled environments without the risks associated with highly pathogenic viruses.

All QR reports Order Now

SARS-CoV-2 Wuhan-Hu-1 Background

The SARS-CoV-2 D614G variant refers to an early and globally dominant form of the virus that carries a point mutation in the spike (S) glycoprotein, in which aspartic acid (D) at position 614 is replaced by glycine (G). This mutation first emerged within the Wuhan-Hu-1 genetic background during the early months of the COVID-19 pandemic and rapidly became the predominant form worldwide, effectively supplanting the ancestral spike sequence in circulating viruses by mid-2020(Korber et al, 2020).
Functionally, the D614G substitution has been associated with increased infectivity and transmission, likely due to structural alterations in the spike protein that favor a conformation more competent for receptor interaction and efficient viral entry, resulting in higher viral loads in infected individuals and enhanced spread at the population level (Yurkovetskiy et al, 2020).
The D614G change has served as a baseline genetic background for subsequent variants of concern that continued to evolve during the pandemic(INSPQ, 2021).

SARS-CoV-1 pseudovirus in Publications

The global impact of COVID-19, caused by the original SARS-CoV-2 strain Wuhan-Hu-1, has highlighted the critical need for effective vaccines and antiviral strategies. By eliminating the need to handle infectious BSL-3 virus, pseudovirus neutralization assays offer a safe, rapid, scalable, and standardized platform for evaluating neutralizing monoclonal antibodies (mAbs) and antiviral compounds targeting the spike (S) protein of SARS-CoV-2.

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation

Order Now

Documentation

Quality Control Reports

Access QR reports

SDS

Access SDS

×

Get your document

Fill out the form below to get your document

"*" indicates required fields

Name*

First Last

Email*

This field is hidden when viewing the form

Document URL